ストックスクリーナーアプリを入手
0.3744
1.38%
0.0051
アフターアワーズ：
.37
-0.0044
-1.18%
前日終値:
$0.3693
開ける：
$0.3545
24時間の取引高:
1.55M
Relative Volume:
0.72
時価総額：
$9.54M
収益：
$476.00K
当期純損益:
$-38.52M
株価収益率:
-0.4141
EPS:
-0.9041
ネットキャッシュフロー:
$-39.89M
1週間 パフォーマンス:
+6.27%
1か月 パフォーマンス:
-4.00%
6か月 パフォーマンス:
-70.29%
1年 パフォーマンス:
-86.82%
1日の値動き範囲:
$0.3527
$0.3866
1週間の範囲:
$0.3466
$0.3866
52週間の値動き範囲:
$0.2805
$4.30
Vyne Therapeutics Inc Stock (VYNE) Company Profile
名前
Vyne Therapeutics Inc
セクター
電話
800-775-7936
住所
685 ROUTE 202/206 N., SUITE 301, BRIDGEWATER
VYNE を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VYNE
Vyne Therapeutics Inc
|
0.3744 | 12.20M | 476.00K | -38.52M | -39.89M | -0.9041 |
|
VRTX
Vertex Pharmaceuticals Inc
|
437.15 | 110.25B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
693.50 | 73.04B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
449.16 | 59.98B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
907.98 | 54.90B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
193.22 | 40.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
Vyne Therapeutics Inc Stock (VYNE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-31 | ダウングレード | BTIG Research | Buy → Neutral |
| 2024-11-18 | 開始されました | BTIG Research | Buy |
| 2021-12-06 | 再開されました | H.C. Wainwright | Buy |
Vyne Therapeutics Inc (VYNE) 最新ニュース
Can VYNE Therapeutics Inc. stock withstand economic slowdown2025 Historical Comparison & Daily Entry Point Trade Alerts - newser.com
Tools to monitor VYNE Therapeutics Inc. recovery probability2025 Technical Overview & Real-Time Stock Movement Alerts - newser.com
What high frequency data says about VYNE Therapeutics Inc.Options Play & Precise Trade Entry Recommendations - newser.com
Is VYNE Therapeutics Inc. stock undervalued vs historical averagesMarket Movement Recap & High Conviction Buy Zone Alerts - newser.com
Published on: 2025-11-14 05:59:36 - newser.com
Will VYNE Therapeutics Inc. stock maintain momentum in 20252025 Bull vs Bear & Safe Capital Growth Tips - newser.com
Is VYNE Therapeutics Inc. showing signs of accumulationWeekly Market Summary & Free Expert Verified Stock Movement Alerts - newser.com
What Wall Street predicts for VYNE Therapeutics Inc. stock priceBreakout Watch & High Return Trade Guides - newser.com
Adversity is less terrifying than hope: VYNE Therapeutics Inc (VYNE) - setenews.com
Using R and stats models for VYNE Therapeutics Inc. forecastingMarket Movement Recap & Long-Term Investment Growth Plans - newser.com
Understanding VYNE Therapeutics Inc.’s price movement2025 Big Picture & Low Risk Entry Point Tips - newser.com
What earnings revisions data tells us about VYNE Therapeutics Inc.Weekly Investment Recap & Step-by-Step Swing Trade Plans - newser.com
Signal strength of VYNE Therapeutics Inc. stock in tech scannersJuly 2025 Outlook & Technical Pattern Based Buy Signals - newser.com
Why analysts remain bullish on VYNE Therapeutics Inc. stockEarnings Miss & Risk Managed Trade Strategies - newser.com
Will VYNE Therapeutics Inc. stock benefit from sector rotationJuly 2025 Intraday Action & Low Drawdown Investment Strategies - newser.com
Published on: 2025-11-09 04:59:05 - newser.com
VYNE Therapeutics Reports Q3 2025 Financial Results - TipRanks
VYNE Achieves Revenue Growth and Advances Strategic Initiatives - GuruFocus
VYNE Therapeutics Cuts Losses And Eyes Strategic Moves - Finimize
[10-Q] VYNE Therapeutics Inc. Quarterly Earnings Report | VYNE SEC FilingForm 10-Q - Stock Titan
VYNE: Net loss improved, costs reduced, and strategic review underway to extend cash runway into 2027 - TradingView
VYNE Therapeutics Inc. (VYNE) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
VYNE Therapeutics Q3 net loss narrows, strategic review ongoing - MarketScreener
VYNE Therapeutics Reports 2025 Third Quarter Financial Results and Provides Business Update - The Manila Times
[8-K] VYNE Therapeutics Inc. Reports Material Event | VYNE SEC FilingForm 8-K - Stock Titan
VYNE Therapeutics (NASDAQ: VYNE) R&D down 48.7%, cash runway into first half of 2027 - Stock Titan
Why VYNE Therapeutics Inc. stock could be next big winnerQuarterly Profit Review & Safe Entry Trade Reports - newser.com
MSN Money - MSN
Vyne Therapeutics Inc (VYNE) 財務データ
収益
当期純利益
現金流量
EPS
1.43%
0.07%
大文字化:
|
ボリューム (24 時間):